| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.02 |
| 52 Week High | CN¥36.54 |
| 52 Week Low | CN¥14.81 |
| Beta | 0.48 |
| 1 Month Change | -2.34% |
| 3 Month Change | -0.74% |
| 1 Year Change | -44.71% |
| 3 Year Change | -40.20% |
| 5 Year Change | 46.48% |
| Change since IPO | 111.29% |
Recent News & Updates
Shareholder Returns
| 2932 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | -1.4% | 5.4% | 1.6% |
| 1Y | -44.7% | -16.4% | -15.1% |
Return vs Industry: 002932 underperformed the CN Medical Equipment industry which returned -16.4% over the past year.
Return vs Market: 002932 underperformed the CN Market which returned -15.1% over the past year.
Price Volatility
| 2932 volatility | |
|---|---|
| 2932 Average Weekly Movement | 8.4% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 002932 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002932's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,547 | Chen Li Li | www.mdeasydiagnosis.com |
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, manufacture, and sale of in-vitro diagnostic products China and internationally. Its products portfolio includes molecular diagnostic products, such as PCR system, nucleic acid extraction and purification instrument, and sample release reagent; blood gas analyzer; immuno diagnosis, including chemiluminescence immunoassay, fluorescence immunity, and immunoquantitative analyzer; and automatic coagulation analyzer.
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Fundamentals Summary
| 2932 fundamental statistics | |
|---|---|
| Market cap | CN¥4.68b |
| Earnings (TTM) | CN¥515.33m |
| Revenue (TTM) | CN¥3.69b |
9.0x
P/E Ratio1.3x
P/S RatioIs 2932 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2932 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.69b |
| Cost of Revenue | CN¥2.02b |
| Gross Profit | CN¥1.67b |
| Other Expenses | CN¥1.15b |
| Earnings | CN¥515.33m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 2.22 |
| Gross Margin | 45.26% |
| Net Profit Margin | 13.98% |
| Debt/Equity Ratio | 2.2% |
How did 2932 perform over the long term?
See historical performance and comparison